Taris

Technology

The TARIS therapeutic system, which was initially developed by which is based on technology developed by the Massachusetts Institute of Technology (MIT) and supported by the Deshpande Center and leading urologists, has two main features: a drug component and a retentive device component. Our approach is an innovative advancement in the field of drug delivery and has the potential to be a less invasive, more effective local treatment option that may also minimize systemic exposure and associated side effects of current therapies.

TARIS is initially focused on developing drug-device convergence products for the local, sustained delivery of drugs to treat bladder diseases. TARIS’ lidocaine-releasing intravesical system (LiRIS) is a passive non-resorbable system whose primary mode of action is the controlled release of lidocaine in the bladder. Lidocaine has been shown in clinical practice and in scientific literature to decrease symptoms such as bladder pain and urgency. The LiRIS system is designed to be inserted into the bladder via cystoscopic or catheter. Over a period of weeks, the LiRIS system will deliver therapeutic agents directly to the bladder, and can then be removed by conventional, non-surgical cystoscopic procedures. See diagram on right.

Bladder